Skip to main content

Kardiale Beteiligung bei Amyloidose

  • Chapter
  • First Online:
Klinische Kardiologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 1337 Accesses

Zusammenfassung

Amyloidosen stellen eine Gruppe von Erkrankungen dar, die durch die Ablagerung von fibrillären Proteinen entsteht. Hierdurch kommt es zur Dysfunktion des betroffenen Organs. Ursächlich kann eine übermäßige Produktion oder eine fehlerhafte Faltung eines physiologisch vorkommenden Proteins sein. Eine Einteilung erfolgt anhand des abgelagerten Vorläuferproteins. Der Verdacht auf eine Amyloidose sollte insbesondere in Betracht gezogen werden, wenn Symptome verschiedener Organsysteme vorliegen. Eine präzise Diagnostik einschließlich Laboruntersuchungen und Biopsie mit Immunhistologie ist für die richtige Therapieauswahl von Bedeutung. Durch Fortschritte in der Diagnostik wird die im Allgemeinen als selten angesehene Erkrankungsgruppe zunehmend häufiger diagnostiziert. Die neuen therapeutischen Optionen führen zu einer positiven Beeinflussung des Krankheitsverlaufs der Patienten. Da die Prognose im Wesentlichen von dem Ausmaß der kardialen Manifestation abhängt, kann in Einzelfällen eine Herztransplantation notwendig sein. Eine interdisziplinäre Betreuung der Patienten in einem spezialisierten Zentrum ist sinnvoll.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 239.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Adams D, Gonzalez-Duarte A, O'Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11–21

    Article  PubMed  Google Scholar 

  • Akinboboye O, Shah K, Warner AL, Damy T, Taylor HA, Gollob J, Powell C, Karsten V, Vest J, Maurer MS (2020) DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid 27(4):223–230

    Article  PubMed  Google Scholar 

  • Aus dem Siepen F, Hein S, Prestel S et al (2019) Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol 108:1324–1330

    Article  PubMed  Google Scholar 

  • Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC (2015) Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac Amyloidosis. Circulation 132(16):1570–1579

    Article  PubMed  PubMed Central  Google Scholar 

  • Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22–31

    Article  PubMed  Google Scholar 

  • Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC (2020) Causes of AA amyloidosis: a systematic review. Amyloid 27(1):1–12

    Article  PubMed  Google Scholar 

  • Connors LH, Sam F, Skinner M et al (2016) Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133:282–290

    Article  PubMed  Google Scholar 

  • Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM (2019) ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Card Fail 25(11):e1–e39

    Article  PubMed  Google Scholar 

  • Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 68(12):1323–1341

    Article  PubMed  Google Scholar 

  • Galant NJ, Westermark P, Higaki JN, Chakrabartty A (2017) Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy. Clin Sci (Lond) 131(5):395–4094

    Article  PubMed  Google Scholar 

  • Gertz MA (2018) Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol 93(9):1169–1180

    Article  PubMed  Google Scholar 

  • Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404–2412

    Article  PubMed  Google Scholar 

  • Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799–2806

    Article  PubMed  Google Scholar 

  • Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A (2016) Natural history of wild- type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68(10):1014–1020

    Article  PubMed  Google Scholar 

  • Kristen AV, Brokbals E, Aus dem SF, Bauer R, Hein S, Aurich M, Riffel J, Behrens HM, Kruger S, Schirmacher P, Katus HA, Rocken C (2016) Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol 68(1):13–24

    Google Scholar 

  • Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007–1016

    Article  PubMed  Google Scholar 

  • Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, Mascherbauer J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R, Ugander M, van Heeswijk RB, Friedrich MG (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European association for cardiovascular imaging (EACVI). J Cardiovasc Magn Reson 19(1):75

    Article  PubMed  PubMed Central  Google Scholar 

  • Nativi-Nicolau JN, Karam C, Khella S et al (2021) Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. https://doi.org/10.1007/s10741-021-10080-2

  • Pagourelias ED, Mirea O, Duchenne J, Van CJ, Delforge M, Bogaert J, Kuznetsova T, Voigt JU (2017) Echo parameters for differential diagnosis in cardiac Amyloidosis: a head-to-head comparison of deformation and Nondeformation parameters. Circ Cardiovasc Imaging 10(3):e5588

    Article  Google Scholar 

  • Palladini G, Milani P, Merlini G (2020) Management of AL amyloidosis in 2020. Blood 136:2620–2627

    Article  PubMed  Google Scholar 

  • Puntmann VO, Peker E, Chandrashekhar Y, Nagel E (2016) T1 mapping in characterizing myocardial disease: a comprehensive review. Circ Res 119(2):277–299

    Article  PubMed  Google Scholar 

  • Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872–2891

    Article  PubMed  PubMed Central  Google Scholar 

  • Silva-Batista JA da, Marques W Jr, Oliveira MTJS, Lins LVC, Galvão AJP, Miguel DSCG, Machado-Costa MC (2020) Presence of Val30Met and Val122Ile mutations in a patient with hereditary amyloidosis. J Hum Genet 65(8):711–713

    Google Scholar 

  • Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, Radu C, Guendouz S, Couetil JP, Benhaiem N, Hittinger L, Dubois-Rande JL, Plante-Bordeneuve V, Mohty D, Deux JF, Damy T (2016) Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging 9(2):126–138

    Article  PubMed  Google Scholar 

  • Vaxman I, Gertz M (2019) Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis. Acta Haematol 141:93–106

    Article  PubMed  Google Scholar 

  • Westermark GT, Fändrich M, Westermark P (2015) AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 10:321–344

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arnt V. Kristen .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kristen, A.V. (2023). Kardiale Beteiligung bei Amyloidose. In: Marx, N., Erdmann, E. (eds) Klinische Kardiologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62932-1_34

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62932-1_34

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62931-4

  • Online ISBN: 978-3-662-62932-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics